Modification of pIX or hexon based on fiberless Ad vectors is not effective for targeted Ad vectors.

[1]  M. Havenga,et al.  Targeting of Adenovirus Serotype 5 (Ad5) and 5/47 Pseudotyped Vectors In Vivo: Fundamental Involvement of Coagulation Factors and Redundancy of CAR Binding by Ad5 , 2007, Journal of Virology.

[2]  S. Nakagawa,et al.  Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon , 2007, Gene Therapy.

[3]  M. Havenga,et al.  Influence of Coagulation Factor Zymogens on the Infectivity of Adenoviruses Pseudotyped with Fibers from Subgroup D , 2007, Journal of Virology.

[4]  C. Johansson,et al.  Adenoviruses Use Lactoferrin as a Bridge for CAR-Independent Binding to and Infection of Epithelial Cells , 2006, Journal of Virology.

[5]  A. Parker,et al.  Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. , 2006, Blood.

[6]  J. Mathis,et al.  Genetic Incorporation of a Herpes Simplex Virus Type 1 Thymidine Kinase and Firefly Luciferase Fusion into the Adenovirus Protein IX for Functional Display on the Virion , 2006, Molecular imaging.

[7]  H. Mizuguchi,et al.  Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. , 2006, Human gene therapy.

[8]  M. Rabelink,et al.  A system for efficient generation of adenovirus protein IX‐producing helper cell lines , 2006, The journal of gene medicine.

[9]  J. Mathis,et al.  Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. , 2005, Virology.

[10]  A. Gaggar,et al.  Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity , 2005, Journal of Virology.

[11]  D. Curiel,et al.  Identification of Sites in Adenovirus Hexon for Foreign Peptide Incorporation , 2005, Journal of Virology.

[12]  M. Magnusson,et al.  Gene Transduction and Cell Entry Pathway of Fiber-Modified Adenovirus Type 5 Vectors Carrying Novel Endocytic Peptide Ligands Selected on Human Tracheal Glandular Cells , 2004, Journal of Virology.

[13]  D. Curiel,et al.  Fluorescently labeled adenovirus with pIX-EGFP for vector detection. , 2004, Molecular imaging.

[14]  R. Parks,et al.  Use of adenovirus protein IX (pIX) to display large polypeptides on the virion--generation of fluorescent virus through the incorporation of pIX-GFP. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  H. Mizuguchi,et al.  Reduction of Natural Adenovirus Tropism to Mouse Liverby Fiber-Shaft Exchange in Combination with both CAR- andαv Integrin-BindingAblation , 2003, Journal of Virology.

[16]  J. Markovits,et al.  Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. , 2003, Human gene therapy.

[17]  G. Nemerow,et al.  Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. , 2003, Human Gene Therapy.

[18]  M. Magnusson,et al.  Adenovirus stripping: a versatile method to generate adenovirus vectors with new cell target specificity. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  H. Mizuguchi,et al.  Generation of fiber‐modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob , 2003, The journal of gene medicine.

[20]  H. Hamada,et al.  Reduction of Natural Adenovirus Tropism to the Liver by both Ablation of Fiber-Coxsackievirus and Adenovirus Receptor Interaction and Use of Replaceable Short Fiber , 2003, Journal of Virology.

[21]  M. Magnusson,et al.  Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability , 2002, The journal of gene medicine.

[22]  H. Mizuguchi,et al.  CAR- or αv integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice , 2002, Gene Therapy.

[23]  M. Rollence,et al.  In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  I. Kovesdi,et al.  Reducing the Native Tropism of Adenovirus Vectors Requires Removal of both CAR and Integrin Interactions , 2001, Journal of Virology.

[25]  H. Mizuguchi,et al.  Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. , 2001, Biochimica et biophysica acta.

[26]  R. Alemany,et al.  CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors , 2001, Gene Therapy.

[27]  C. Kedinger,et al.  Functional Analysis of Adenovirus Protein IX Identifies Domains Involved in Capsid Stability, Transcriptional Activity, and Nuclear Reorganization , 2001, Journal of Virology.

[28]  T. Mayumi,et al.  Optimization of transcriptional regulatory elements for constructing plasmid vectors. , 2001, Gene.

[29]  M. Kay,et al.  A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob , 2001, Gene Therapy.

[30]  D. Curiel,et al.  Genetic Targeting of an Adenovirus Vector via Replacement of the Fiber Protein with the Phage T4 Fibritin , 2001, Journal of Virology.

[31]  M. Bewley,et al.  Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. , 1999, Science.

[32]  I. Kovesdi,et al.  Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. , 1999, Science.

[33]  A. Beavil,et al.  Mutations in the DG Loop of Adenovirus Type 5 Fiber Knob Protein Abolish High-Affinity Binding to Its Cellular Receptor CAR , 1999, Journal of Virology.

[34]  M. Kay,et al.  A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. , 1999, Human gene therapy.

[35]  C. Miller,et al.  A system for the propagation of adenoviral vectors with genetically modified receptor specificities , 1999, Nature Biotechnology.

[36]  D. Spehner,et al.  Fiberless Recombinant Adenoviruses: Virus Maturation and Infectivity in the Absence of Fiber , 1999, Journal of Virology.

[37]  P. Stewart,et al.  A Helper-Independent Adenovirus Vector with E1, E3, and Fiber Deleted: Structure and Infectivity of Fiberless Particles , 1999, Journal of Virology.

[38]  M. Kay,et al.  Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. , 1998, Human gene therapy.

[39]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[40]  J. Deisenhofer,et al.  Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli , 1994, Journal of virology.

[41]  R. M. Burnett,et al.  Adenovirus polypeptide IX revealed as capsid cement by difference images from electron microscopy and crystallography. , 1989, The EMBO journal.

[42]  F. Graham,et al.  Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. , 1987, The EMBO journal.

[43]  T. Shenk,et al.  Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX , 1981, Journal of virology.

[44]  J. Maizel,et al.  The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. , 1974, Virology.

[45]  M. Perricaudet,et al.  Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation , 2003, Gene Therapy.

[46]  S. Cusack,et al.  Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism , 2001, Gene Therapy.

[47]  E. Kremmer,et al.  Specific detection of his-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions. , 1997, BioTechniques.